Momenta’s Decision To Ditch Abatacept Makes Orencia Dispute Moot
Executive Summary
Abandoning development of a biosimilar removes any right to challenge patents protecting the reference biologic, the US Court of Appeals has stated in dismissing Momenta’s appeal over abatacept.
You may also be interested in...
Momenta plans exit of Mylan biosimilars
Momenta Pharmaceuticals has “initiated discussions” with partner Mylan to exit its participation in the development of five biosimilar programs, including the firms’ M834 biosimilar Orencia (abatacept) candidate, after completing a strategic review “aimed at reducing costs of biosimilar development” and focusing its resources on its pipeline of novel drug candidates.
Pressure Mounts For German Tender Reforms
Germany’s off-patent industry association, Pro Generika, is finding ample support for its position that by awarding tender contracts to exclusive suppliers, health insurance funds are contributing to drug shortages in the country.
Teva Leapfrogs Mylan And Sandoz On Linaclotide
A patent-litigation settlement that Teva has reached with Ironwood and Allergan over Linzess will allow the Israeli firm to enter the US market with the linaclotide-based constipation treatment ahead of major rivals Mylan, Sandoz, Sun Pharma and Aurobindo.